ConvaTec (CNVVF)
OTHER OTC:CNVVF
CNVVF Stock Chart & Stats
$2.91
-$0.11(-3.51%)
At close: 4:00 PM EST
$2.91
-$0.11(-3.51%)
Day’s Range― - ―
52-Week Range$2.63 - $4.28
Previous CloseN/A
Volume350.00
Average Volume (3M)3.56K
Market Cap
$5.60B
Enterprise Value$7.40B
Total Cash (Recent Filing)$75.03M
Total Debt (Recent Filing)$1.61B
Price to Earnings (P/E)37.1
Beta0.31
Next Earnings
Aug 04, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield2.11%
Share Statistics
EPS (TTM)0.10
Shares Outstanding1,954,852,000
10 Day Avg. Volume10,328
30 Day Avg. Volume3,561
Financial Highlights & Ratios
PEG Ratio-7.34
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit5.43
Enterprise Value/Ebitda11.95
Forecast
1Y Price Target
$4.20Price Target Upside44.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$34.51M
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthSustained organic growth across core chronic‑care categories shows durable end‑market demand and recurring consumable revenue. Multi‑year targets and five years >5% provide a predictable top‑line base that supports capacity planning, R&D, and phased product launches, reducing reliance on cyclical volumes and aiding mid‑term forecasting.
Operating Margin Expansion And TargetMeaningful margin improvement (460 bps since 2021) reflects structural productivity, pricing and portfolio mix gains rather than one‑off items. A sustained mid‑20s operating margin target implies ongoing cost programs and pricing power that should enhance cash generation, fund growth CapEx and support shareholder returns over the medium term.
Strong Free Cash Flow And Capital ReturnsHigh FCF conversion and an active buyback/dividend program demonstrate resilient cash generation and disciplined capital allocation. Reliable cash supports growth CapEx for capacity, funds deleveraging or strategic M&A, and provides flexibility to sustain returns even as management increases investment to scale new product launches.
Bears Say
Increased Leverage And Debt SensitivityHigher leverage reduces financial flexibility and raises interest‑rate and earnings‑shock sensitivity. Even with strong FCF, elevated net debt/EBITDA constrains strategic optionality, increases fixed financing costs and could force slower buybacks or delayed investments under adverse conditions, raising medium‑term downside risk.
FDA Warning Letter — Compliance/process RiskA formal FDA warning requires process remediation, potential inspections, and sustained management attention. Remediation costs, possible distribution constraints, or follow‑up enforcement could delay launches, absorb R&D/operations resources, and create reputational friction with hospital customers, posing a persistent operational risk until closed.
Reimbursement Shock And Asset Impairment (InnovaMatrix)A material CMS reimbursement cut and related impairment highlight vulnerability to regulator‑driven pricing shifts. Such policy changes can permanently compress product economics, reduce ROI on acquisitions, and create channel/legal uncertainty that limits recovery prospects and forces reprioritization of portfolio investments over the medium term.
ConvaTec News
CNVVF FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was $2.63 and its highest was $4.28 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is $5.60B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 116 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported $0.097 earnings per share for the quarter, missing the consensus estimate of $0.1 by -$0.003.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of $0.019 which represents an annual dividend yield of 2.11%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.09.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of $0.097 in its last earnings report, missing expectations of $0.1. Following the earnings report the stock price went up 10.033%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in CNVVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.20 (44.31% Upside)
$4.20 (44.31% Upside)
Insider Transactions
Sold Shares
Worth £747.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.50%
12-Months-Change
Fundamentals
Return on Equity
10.53%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
CNVVF Stock 12 Month Forecast
Average Price Target
$4.20
▲(44.31% Upside)
Technical Analysis
Ownership Overview
0.19% Insiders
12.82% Mutual Funds
<0.01% Other Institutional Investors
80.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---